Quantcast
Last updated on April 19, 2014 at 7:09 EDT

Latest Placebo-controlled study Stories

2012-02-07 08:15:00

SCHOFIELD, Wis., Feb. 7, 2012 /PRNewswire/ -- PuraMed BioScience, Inc. (OTC QB: PMBS) announced today that it has recently commenced a clinical study of its unique non-prescription migraine treatment, LipiGesic®M on children and adolescents. Currently there are no prescription migraine medications recommended for those under the age of 18, and PuraMed hopes to attract that market with the results from this upcoming study. "We are very excited to begin the clinical study of...

2012-01-17 17:21:00

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from the Bayer HealthCare Phase 3 CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial of Bayer's investigational compound regorafenib (BAY 73-4506). The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months...

2011-12-21 10:11:21

Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA. "Antihypertensive drug therapy has been shown to decrease nonfatal and fatal cardiovascular events in controlled clinical trials and...

2011-12-21 05:00:00

SCHOFIELD, Wis., Dec. 21, 2011 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB: PMBS) announced today, an outline of its plans for the national product launch of its clinically tested migraine treatment LipiGesic(R) M. The Company has always emphasized science as the key to their success and this year three of the top headache researchers in the United States conducted a Double-blind, Placebo controlled, clinical trial of LipiGesic(R) M. The study was peer reviewed and published in the...

2011-12-12 06:00:00

PRINCETON, N.J., Dec. 12, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell...

2011-11-09 09:00:00

DURHAM, N.C., Nov. 9, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences in New York City: the 8th Annual Lazard Healthcare Conference on November 16th at 10:30 am at The Pierre Hotel and the 23rd Annual Piper Jaffray Health Care Conference on November 29 at 11:50 am at The New York Palace. Mr. Moch's...

2011-10-05 07:30:00

NEW YORK, Oct. 5, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that a manuscript entitled "Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine as Second- or Third-Line Therapy in Patients with Metastatic Colorectal Cancer" reporting Phase 2 activity of KRX-0401 (perifosine) in the treatment of patients with refractory, advanced colorectal cancer (mCRC), was selected for publication in the October 3, 2011 online...

2011-10-03 06:00:00

RICHMOND, Calif., Oct. 3, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo. "We are disappointed that this trial did not produce a better outcome in the pre-specified primary and secondary endpoints," said Edward Lanphier, Sangamo's president and CEO. "Based on these results, we will...

2011-09-26 05:15:00

AMSTERDAM, Sept. 26, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ:ITMN) today reported that new data(1) was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(®) (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease. Approximately 30,000-35,000 new IPF patients are diagnosed in Europe each year, with an estimated median survival of only two to five...

2011-09-21 15:30:00

S-Equol Study simultaneously published in MENOPAUSE and presented at North American Menopause Society Annual Meeting WASHINGTON, Sept. 21, 2011 /PRNewswire-USNewswire/ -- A soy germ-based nutritional supplement containing Natural S-equol significantly improved the appearance of crow's feet skin wrinkles of the outer corner of the eyes in Japanese menopausal women, suggesting that supplements containing Natural S-equol have potential to slow skin aging, according to data from a controlled...